Andre Macedo Dias, MD
Cardiovascular Disease · Jacksonville, FLNPI 1013221282
Payments from drug & device makers
Across 387 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Boehringer Ingelheim$827
- Merck$766
- Pfizer$646
- AstraZeneca$638
- Novartis$611
- plus $4K from 30 others
What the payments were for
- Food & beverage$8,15099%
- Education$481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 43 | $1,101 |
| Boehringer Ingelheim | 40 | $827 |
| Merck | 40 | $766 |
| Pfizer | 31 | $646 |
| AstraZeneca | 33 | $638 |
| Novartis | 30 | $611 |
| Abbott | 6 | $453 |
| Johnson & Johnson | 25 | $379 |
| Novo Nordisk | 19 | $368 |
| E.r. Squibb & Sons, L.L.C. | 19 | $309 |
| Amgen | 17 | $291 |
| Actelion Pharmaceuticals US, Inc. | 11 | $251 |
| Esperion Therapeutics, Inc. | 11 | $233 |
| Sanofi-aventis U.S. LLC | 8 | $152 |
| Kestra Medical Technology Services, Inc. | 6 | $144 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $94 |
| Regeneron Healthcare Solutions, Inc. | 4 | $94 |
| Scpharmaceuticals Inc. | 5 | $82 |
| Impulse Dynamics (USA) Inc. | 3 | $76 |
| Alnylam Pharmaceuticals Inc. | 3 | $75 |
| Philips North America LLC | 2 | $68 |
| Lexicon Pharmaceuticals, Inc. | 3 | $67 |
| Sanofi | 2 | $64 |
| Baxter Healthcare | 4 | $63 |
| Bayer | 3 | $58 |
| Amarin Pharma, Inc. | 3 | $57 |
| Bridgebio Pharma, Inc. | 2 | $50 |
| Cvrx, Inc. | 1 | $27 |
| Endotronix, Inc. | 1 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Braemar Manufacturing, LLC | 1 | $23 |
| Medtronic | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Terumo Medical Corporation | 1 | $17 |
| Gilead | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$221
- MitraClip$154
- MitraClip System$128
- TRICLIP$109
How this compares
$8,198 in reported general payments places this provider in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 243 | $300,810 |
| EntrestoSacubitril/Valsartan | 98 | $115,883 |
| XareltoRivaroxaban | 87 | $86,911 |
| Repatha SureclickEvolocumab | 84 | $71,548 |
| OzempicSemaglutide | 34 | $54,306 |
| JardianceEmpagliflozin | 42 | $46,275 |
| FarxigaDapagliflozin Propanediol | 28 | $33,129 |
| Repatha SyringeEvolocumab | 15 | $6,438 |
| Atorvastatin Calcium | 228 | $2,437 |
| Nifedipine ErNifedipine | 144 | $2,212 |
| Carvedilol | 232 | $2,194 |
| Metoprolol Succinate | 181 | $2,087 |
| Ranolazine ErRanolazine | 29 | $1,763 |
| ClopidogrelClopidogrel Bisulfate | 97 | $1,426 |
| Labetalol Hcl | 48 | $1,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $646 | $300,810243 claims |
| NovartisEntresto | $611 | $115,88398 claims |
| Johnson & JohnsonXarelto | $379 | $86,91187 claims |
| Novo NordiskOzempic | $368 | $54,30634 claims |
| Boehringer IngelheimJardiance | $827 | $46,27542 claims |
| AstraZenecaFarxiga | $638 | $33,12928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Jacksonville
- Francesco FranchiJacksonville$1.6M
- Jose Nativi-NicolauJacksonville$1.5M
- Edward PereiraJacksonville$1.1M
- Alan MillerJacksonville$756K
- Ameeth VedreJacksonville$661K
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- William OneillNaples$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.